Stocktoria
Coya Therapeutics, Inc. COYA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-12-29
Coya Therapeutics, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M | -$4.9M |
| Income tax | $3,089 | -$720,287 | $723,852 | $0 | — |
| Net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M | -$4.9M |
| EPS (diluted) | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
| Operating cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M | -$3.9M |
| Cash & equivalents | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M |
| Shareholders' equity | $43.0M | $39.6M | $35.6M | -$8.4M | $3.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | +123.6% | -40.8% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.